Skip to content

The median effective dose of oxeridine combined with propofol for painless fiberoptic bronchoscopy

The median effective dose of oxeridine combined with propofol for painless fiberoptic bronchoscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095811
Enrollment
Unknown
Registered
2025-01-13
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless fiberoptic bronchoscopy

Interventions

Group A:Ocelidine was slowly injected intravenously according to the modified sequential method, and propofol 0.4 mg/kg was slowly injected intravenously over

Sponsors

the Second Hospital of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing painless fiberoptic bronchoscopy were aged 18 to 65 years, BMI 18 to 28 kg/m^2, and ASA class I or II.

Exclusion criteria

Exclusion criteria: 1.Patients with contraindications to general anesthesia or a history of anesthesia accidents, known or suspected allergies or contraindications to propofol injection excipients, oxycellidine, etc., severe physical weakness or major diseases of the heart, lungs, liver, kidneys, brain, etc., abuse or long-term use of anesthetics, sedatives, and analgesics, a history of mental illness, surgery lasting more than 30 minutes or inability to communicate.

Design outcomes

Primary

MeasureTime frame
Movement response;

Secondary

MeasureTime frame
Respiratory depression;Hypoxemia;

Countries

China

Contacts

Public ContactXu Hai

the Second Hospital of Jiaxing

xhjxey@163.com+86 573 82080930

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026